The Defense Health Agency awarded a $970,871 Project Grant to Brigham & Women's Hospital Inc. for the project "TARGETING METASTATIC LUNG TUMORS WITH GENE-EDITED AND ENGINEERED STEM CELLS". The grant, funded through the Military Medical Research and Development program (CFDA 12.420), aims to develop innovative treatments for lung cancer and other conditions relevant to military personnel and civilians. Brigham & Women's Hospital, a non-profit healthcare and research institution, will lead the 3-year project to investigate the use of gene-edited and engineered stem cells for targeting metastatic lung tumors. Partners Healthcare System Incorporated, the parent organization of Brigham & Women's, may provide additional administrative support for this grant. The project is part of the Defense Health Agency's efforts to transform healthcare through impactful biomedical research.